Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.
Urothelial carcinoma (UC) accounts for 5% to 10% of malignancies in men in Europe and the United States. For locally advanced or metastatic disease, there are two standard firstline chemotherapy regimens: MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) and gemcitabine/cisplatin. For refract...
Main Authors: | Morel, A, Talbot, D |
---|---|
פורמט: | Journal article |
שפה: | English |
יצא לאור: |
Dove Medical Press Ltd.
2010
|
פריטים דומים
-
Second line therapy for metastatic urothelial carcinoma. Clinical case of vinflunine use
מאת: A. A. Gritskevich, et al.
יצא לאור: (2022-06-01) -
From clinical trials to the front line: Vinflunine for Treatment of UrothelialCell Carcinoma at the National Cancer Institute of Naples
מאת: GAETANO eFACCHINI, et al.
יצא לאור: (2016-05-01) -
Vinflunine in the treatment of bladder cancer
מאת: Mark Bachner, et al.
יצא לאור: (2008-11-01) -
A Prospective Study of I.V. Vinflunine in the Treatment of Patients with Advanced or Metastatic Urothelial Carcinoma after Failure of a Platinum-containing Regimen and Biomarker Correlates
מאת: Fatma M.A. Abouelkasem, et al.
יצא לאור: (2022-08-01) -
Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01–2014)
מאת: Rodolfo Passalacqua, et al.
יצא לאור: (2017-07-01)